Meeting documents & Info


About the Meeting

Objectives of the meeting

One of the proposed tools for faster development of new vaccines is CHIM: Controlled Human Infectious Models. These models can be used for early PoC (Proof of Concept) and as a basis for clinical “Go/No Go” decisions, in particular if sporadic epidemiology impedes clinical development.
In these models researchers will use a challenge agent: a virus, bacterium or parasite. Frequently questions are raised on the quality of the agent. Should this agent be produced following GMP? What strain-related information is relevant? Should it be attentuated or resemble the wild type?

Scientific committee

Dr. Isabelle Bekeredjian-Ding
Paul-Ehrlich-Institut (PEI), Germany
Dr. Wim van Molle
Sciensano, Belgium
Dr. Heidi Meyer
Paul-Ehrlich-Institut (PEI), Germany
Dr. Christoph Conad
Paul-Ehrlich-Institut (PEI), Germany
Dr. Richard Rupp
University of Texas Medical Branch, U.S.A.
Dr. Nele Berthels
Federal Agency for Medicines and Health Products (FAMHP), Belgium
Dr. William Ripley Ballou
GlaxoSmithKline, U.S.A.